Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled trial of riluzole in spinocerebellar ataxia type 2
2017-001481-23Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Spinocerebellar Ataxia Type 2 (SCA2) comparing Riluzole with Placebo (2 arms). Primary endpoint: Proportion of patients with SARA score improved by at least one point at 12 months. Started Oct 2017; status: completed.
02
Drugs
riluzole
03
Conditions
Spinocerebellar Ataxia Type 2 (SCA2)
Beyond the preview
Go deeper on 2017-001481-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001481-23.